WARRINGTON, Pa., Nov. 16, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (NasdaqGM:DSCO - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted Discovery Labs’ submission of November 1, 2007 as a complete response to the April 2006 Approvable Letter for Surfaxin(r) (lucinactant), for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA has established May 1, 2008 as its target date to complete its review of the Surfaxin New Drug Application (NDA).